164 related articles for article (PubMed ID: 16409125)
1. Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.
Bieler A; Mantwill K; Dravits T; Bernshausen A; Glockzin G; Köhler-Vargas N; Lage H; Gansbacher B; Holm PS
Hum Gene Ther; 2006 Jan; 17(1):55-70. PubMed ID: 16409125
[TBL] [Abstract][Full Text] [Related]
2. Impact of radiation therapy on the oncolytic adenovirus dl520: implications on the treatment of glioblastoma.
Bieler A; Mantwill K; Holzmüller R; Jürchott K; Kaszubiak A; Stärk S; Glockzin G; Lage H; Grosu AL; Gansbacher B; Holm PS
Radiother Oncol; 2008 Mar; 86(3):419-27. PubMed ID: 17967494
[TBL] [Abstract][Full Text] [Related]
3. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
4. Coxsackievirus and adenovirus receptor promotes antitumor activity of oncolytic adenovirus H101 in esophageal cancer.
Ma J; Zhao J; Lu J; Jiang Y; Yang H; Li P; Zhao M; Liu K; Dong Z
Int J Mol Med; 2012 Dec; 30(6):1403-9. PubMed ID: 22992863
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
[TBL] [Abstract][Full Text] [Related]
6. The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.
Berghauser Pont LM; Kleijn A; Kloezeman JJ; van den Bossche W; Kaufmann JK; de Vrij J; Leenstra S; Dirven CM; Lamfers ML
PLoS One; 2015; 10(5):e0127058. PubMed ID: 25993039
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
[TBL] [Abstract][Full Text] [Related]
8. Expression of the coxsackie adenovirus receptor in neuroendocrine lung cancers and its implications for oncolytic adenoviral infection.
Wunder T; Schmid K; Wicklein D; Groitl P; Dobner T; Lange T; Anders M; Schumacher U
Cancer Gene Ther; 2013 Jan; 20(1):25-32. PubMed ID: 23196273
[TBL] [Abstract][Full Text] [Related]
9. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
10. In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL.
El-Zawahry A; Lu P; White SJ; Voelkel-Johnson C
Cancer Gene Ther; 2006 Mar; 13(3):281-9. PubMed ID: 16167063
[TBL] [Abstract][Full Text] [Related]
11. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
12. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy.
Lamfers ML; Grill J; Dirven CM; Van Beusechem VW; Geoerger B; Van Den Berg J; Alemany R; Fueyo J; Curiel DT; Vassal G; Pinedo HM; Vandertop WP; Gerritsen WR
Cancer Res; 2002 Oct; 62(20):5736-42. PubMed ID: 12384532
[TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
Cheema TA; Kanai R; Kim GW; Wakimoto H; Passer B; Rabkin SD; Martuza RL
Clin Cancer Res; 2011 Dec; 17(23):7383-93. PubMed ID: 21976549
[TBL] [Abstract][Full Text] [Related]
14. The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells.
Katsura T; Iwai S; Ota Y; Shimizu H; Ikuta K; Yura Y
Cancer Gene Ther; 2009 Mar; 16(3):237-45. PubMed ID: 18949013
[TBL] [Abstract][Full Text] [Related]
15. [Enhancive effect of histone deacetylase inhibitor trichostatin a on transfection efficiency of adenovirus in ovarian carcinoma cell line A2780].
Chen G; Wang BB; Li FJ; Liu DY; Zhou JF; Lu YP; Ma D
Ai Zheng; 2005 Oct; 24(10):1196-200. PubMed ID: 16219132
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide renders murine cancer cells susceptible to oncolytic adenovirus replication and oncolysis.
Garza-Morales R; Yaddanapudi K; Perez-Hernandez R; Riedinger E; McMasters KM; Shirwan H; Yolcu E; Montes de Oca-Luna R; Gomez-Gutierrez JG
Cancer Biol Ther; 2018 Mar; 19(3):188-197. PubMed ID: 29252087
[TBL] [Abstract][Full Text] [Related]
17. The antitumor effects of oncolytic adenovirus H101 against lung cancer.
Lei J; Li QH; Yang JL; Liu F; Wang L; Xu WM; Zhao WX
Int J Oncol; 2015 Aug; 47(2):555-62. PubMed ID: 26081001
[TBL] [Abstract][Full Text] [Related]
18. A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth.
Yoon AR; Hong J; Yun CO
Oncotarget; 2015 Oct; 6(33):34875-91. PubMed ID: 26430798
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy.
Höti N; Chowdhury W; Hsieh JT; Sachs MD; Lupold SE; Rodriguez R
Mol Ther; 2006 Dec; 14(6):768-78. PubMed ID: 16990052
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells.
Sachs MD; Ramamurthy M; Poel Hv; Wickham TJ; Lamfers M; Gerritsen W; Chowdhury W; Li Y; Schoenberg MP; Rodriguez R
Cancer Gene Ther; 2004 Jul; 11(7):477-86. PubMed ID: 15118762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
